ALHC Alignment Healthcare, Inc. Insider Trading

ALHC President Maroney sells 177.1K shares at $20.83 (scheduled 10b5-1 plan); holds 922.3K post-sale amid weak fundamentals

President Dawn Christine Maroney sold 177,068 shares at $20.83 on 2026-07-15 as part of a pre-arranged 10b5-1 trading plan, reducing non-derivative holdings by 16.1% to 922,313 shares. The company's fundamentals remain challenged: annual revenue growth of 46.1% to $1.2B masks persistent unprofitability (negative full-year net income) and an elevated P/E of 200.30, while the stock has declined 20.3% from its 52-week high. Her prior five trades at ALHC show mixed outcomes (30-day returns ranging from -24.6% to +19.7%, 90-day from -21.1% to +13.0%), with no clear directional pattern. The scheduled nature of this sale via 10b5-1 plan removes discretionary intent as a signal; the trade reflects predetermined execution rather than a timing-driven conviction statement.

CEO John E Kao sold 298,000 shares (298.0K) for $5,919,361.03 via scheduled 10b5-1 plan

John E Kao, CEO of Alignment Healthcare, executed 2 separate sales totaling 298,000 shares for $5,919,361.03 on 2026-07-10 via a pre-arranged 10b5-1 trading plan, reducing his holdings from 1,386,766 to 1,088,766 shares. The transaction was scheduled rather than discretionary, so it does not reflect a timing decision by the CEO. Prior trades by Kao at ALHC show mixed near-term outcomes (30-day returns ranging from +22.0% to -12.2%), providing no clear pattern of predictive value at this ticker. The company's fundamentals show rapid revenue growth of +46.1% year-over-year, but a high P/E of 212.00 and recent full-year unprofitability warrant context in evaluating the stock's valuation.

ALHC President sells 30,000 shares at $19.55 via pre-arranged 10b5-1 plan; post-transaction holdings 947.3K shares.

President Maroney executed a scheduled sale of 30,000 shares (30.0K shares) for $586,425.00 ($586.4K) via a pre-arranged 10b5-1 trading plan, reducing her holdings by 3.1% to 947.3K shares. The transaction occurred while ALHC trades at -17.1% from its 52-week high of $23.87, and notably, Maroney's prior trade at this ticker on 2026-04-15 registered a -24.6% return over 30 days, signaling adverse timing outcomes in her recent ALHC-specific activity. Against broader context, ALHC's full-year net income was negative and the company sports a P/E of 197.80 with revenue of $1.2B, reflecting a high-valuation, early-stage profitability profile. Since this sale is governed by a pre-arranged plan, the transaction lacks discretionary intent signals; however, the convergence of a negative full-year result, elevated valuation multiples, and the -24.6% 30-day loss on her prior same-ticker sale warrants attention to ALHC's operational trajectory.

CMO Hyong Kim sells 36.0K shares of ALHC at $19.86 for $713.9K under 10b5-1 plan; stock up 25.8% in 30 days.

Hyong Kim, Chief Medical Officer, sold 35,951 shares at $19.86 on 2026-06-12 as part of a pre-arranged 10b5-1 trading plan, reducing holdings by 9.8% to 331,750 shares. The sale occurred after a 30-day gain of 25.8%, though the stock remains -17.1% from its 52-week high of $23.87. His three prior sales at ALHC generated 90-day returns of +19.1%, +23.2%, and +29.6%, while his cross-ticker track record across all open-market activity shows an average 90-day return of +24.0% following sales. The company reported annual revenue growth of 46.1% and $1.2B quarterly revenue, but remained unprofitable on a full-year basis with a P/E of 197.80, reflecting early-stage growth dynamics where the market is pricing in future profitability.

CEO John E Kao sells 298,000 shares (298.0K) for $6,066,620.78 via scheduled 10b5-1 plan

John E Kao, CEO of Alignment Healthcare, executed 2 separate sales totaling 298,000 shares for $6,066,620.78 on 2026-06-10, reducing his post-transaction holdings to 1,386,766 shares (-17.7% vs pre-transaction holdings). This transaction is part of a pre-arranged 10b5-1 trading plan and therefore reflects a scheduled, non-discretionary execution rather than a discretionary decision made at this moment. The company trades at a P/E of 197.50 and reported full-year net income that was negative despite quarterly revenue of $1,235,197,000.00 and strong FY revenue growth of +46.1%, indicating significant unprofitability at the consolidated level. His prior five trades at ALHC show mixed outcomes, with two May sells showing +22.0% and +17.2% 30-day returns followed by three April sales showing negative 30-day returns (-12.2%, -12.9%, -16.1%), suggesting volatility in near-term stock performance around his trading activity.

Mark D. Kent (President - MSO) purchases 14,848 shares of ALHC at $13.31 as stock down 42.9% from 52-week high.

Mark D. Kent, President of Alignment Healthcare's MSO division, initiated a new position of 14,848 shares at $13.31 on 2026-06-02, purchasing approximately $197,626.88 in stock. This entry comes during a period of significant price weakness: the stock is trading 42.9% below its 52-week high of $23.87, down 32.7% over the prior 30 days and 27.8% over 90 days. Notably, the company is trading at a P/E of 136.40 despite reporting full-year net income that was negative, indicating the equity currently prices in future profitability improvements. The concurrent strength in fundamentals (annual revenue growth of +46.1%, latest-quarter revenue of $1,235,197,000.00) provides context for the purchase timing relative to stock-price depreciation.

ALHC CEO John Kao sells roughly 298k shares in two tranches; stock trading well below 52-week highs amid unprofitable fundamentals.

CEO John Kao disposed of approximately 298,000 shares across two transactions, reducing his stake by a combined sixteen percent—a material liquidation for a top executive. This sale is the sixth and seventh of Kao's open-market exits at ALHC over the past three years, underscoring a consistent seller posture. The company remains unprofitable despite strong revenue growth, and the stock is trading well below its 52-week high while down over the past month, creating an unfavorable backdrop for executive selling. What stands out is Kao's execution track record: his five prior sales at ALHC were all well-timed at both the 30-day and 90-day horizons—in each case the stock declined after he sold—suggesting he has successfully identified weak periods to exit. Placing these two additional sales in that consistent pattern raises a question about whether near-term price weakness signals operational headwinds the market has not yet fully priced in.

President Maroney Dawn Christine sold 30,000 shares of ALHC at $20.87; stock +19.5% in 30 days post-sale despite her 80% well-timed sell rate cross-ticker.

Maroney sold 30,000 shares (-2.8% of pre-transaction holdings) at $20.87 on 2026-04-15, reducing her stake to 1,028,813 shares. Notably, the stock has risen 19.5% in the 30 days following this sale, departing from her cross-ticker track record where she has achieved a 80.00% well-timed sell rate with an average 90-day return of -7.1% after her sells. At the same ticker, her prior four measurable sells have shown positive 30-day returns (+19.7%, +20.6%, +17.3%, -12.0%), suggesting a pattern of selling before rallies rather than declines. The company remains unprofitable on a full-year basis despite 46.1% annual revenue growth, and the stock trades at a 40.23 P/E multiple, creating an asymmetric risk environment where insider sells into strength warrant attention.

CEO John E. Kao sold 298,000 shares (298.0K shares) for $6,161,942.61 across 3 transactions at blended average $20.68

John E. Kao, CEO of Alignment Healthcare, executed 3 separate sales totaling 298,000 shares for $6,161,942.61 on April 10 and April 13, 2026, reducing his holdings by 14.2% to 1,806,641 shares. The company trades at a P/E of 40.35 with 46.1% annual revenue growth but reported negative full-year net income, presenting a high-valuation growth profile balanced against unprofitability concerns. At his same ticker (ALHC), Kao's 5 prior trades in March and early April have not yet demonstrated measurable 90-day outcomes; his cross-ticker track record shows a 90-day well-timed sell rate of 41.67%, indicating mixed historical execution. The current share price of $20.98 remains 11.9% below the 52-week high of $23.81, and the sales occurred after the stock gained +23.5% over the preceding 30 days, suggesting sales during a period of recent strength.

CEO Kao sells 250,000 shares (10.6% of holdings) at blended average $21.01; stock up 17.0% in 30 days but CEO has 25.00% well-timed sell rate cross-ticker.

John E. Kao, Chief Executive Officer of Alignment Healthcare, Inc., executed 2 separate sales totaling 250,000 shares for $5,252,910.60 on 2026-04-07, bringing his post-transaction holdings to 2,104,641 shares. The sales occurred at $20.67 and $21.40 per share (blended average $21.01), in a market context where the stock is currently at $21.31 and has risen 17.0% over 30 days. Across his open-market trade history on all tickers, Kao has achieved a 25.00% well-timed sell rate (90-day basis), suggesting a pattern of identifying peaks; however, his 5 prior trades at ALHC remain too recent to measure outcomes. The company is currently trading at a P/E of 40.98 with recent quarterly revenue of $993,695,000.00, though it was unprofitable over its most recent full fiscal year.